Prospective 2-year Data Collection of the First 10 Patients After Ankle Spacer Implantation

Sponsor
Hannover Medical School (Other)
Overall Status
Completed
CT.gov ID
NCT04297449
Collaborator
(none)
8
1
31.5
0.3

Study Details

Study Description

Brief Summary

Osteochondral defects (OCD) of the talus are pathologic lesions of the talar cartilage and its subchondral bone and might severely deteriorate the quality of life. For the treatment of multiple and/or large talar OCDs and in patients with failed previous surgical treatment the Ankle Spacer was developed. Six patients are included in a prospective clinical and radiological study with a follow-up of two years.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    One surgeon in the investigator's center implanted 10 Ankle Spacers between April 2018 and October 2020. The average age was 41.7 years (20 - 70 years). All patients get a standard followed-up at 6 weeks, 12 weeks. After the first four patients, all following patients are enrolled in a prospective study and where followed up after 1 and 2 years additionally. The American Orthopaedic Foot and Ankle Society (AOFAS) Score, the Foot and Ankle Outcome Score (FAOS), the European Foot and Ankle Score (EFAS), the Visual Analogue Scale (VAS) for pain are collected. Radiographic parameters such as implant loosening, cystic changes, lateral/medial prominence of the implant, congruency to the talar rounding, progression of osteoarthritis or bone ware of the tibia plafond are recorded. The Ankle Spacer is a one-piece implant system that replaces the articulating upper talus surface of the tibio-talar joint, and offers several implant sizes in order to fit to the different talus sizes. It is anatomically designed to the native upper talus surface to provide an optimal fit to the distal articular surface. It has a rough titanium plasma spray (TPS) coated under surface with two posts and spikes for implant fixation. The rough surface enables secondary fixation by means of bone ingrowth and the spikes at the posterior part of the prosthesis allowing for optimal adherence of the implant and for minimal iatrogenic damage upon fixation. By these means, the anatomical situation and the natural congruency of the ankle joint are mirrored to an optimal extent.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    8 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Prospective 2-year Data Collection of the First 10 Patients After Ankle Spacer
    Actual Study Start Date :
    Jan 18, 2019
    Actual Primary Completion Date :
    Jan 19, 2021
    Actual Study Completion Date :
    Sep 3, 2021

    Outcome Measures

    Primary Outcome Measures

    1. Prospective 2-year Data Collection of the First 10 Patients after Ankle Spacer Implantation [2 Years]

      Prospective 2-year Data Collection of the First 10 Patients after Ankle Spacer Implantation

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Women and men aged 18-80 years

    • Indication for implantation of the ankle spacer

    Exclusion Criteria:
    • Florid infections

    • Relevant circulatory disorders on the affected leg

    • Malposition of the OSG (upper ankle Joint) greater than 5 ° varus or valgus

    • Fractures of the OSG or near the ankle that were less than 6 months ago

    • Obesity with a BMI greater than 30 kg / m2

    • Known insulin-dependent diabetes mellitus

    • Known rheumatoid Arthritis

    • Osteoarthritis of the OSG II ° or higher according to Kellgren / Lawrence

    • Deformation of the OSG, which does not allow implantation of the ankle spacer

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Orthopädische Klinik der Medizinischen Hochschule Hannover im DIAKOVERE Annastift Hanover Niedersachsen Germany 30625

    Sponsors and Collaborators

    • Hannover Medical School

    Investigators

    • Principal Investigator: Matthias Lerch, PD Dr., Orthopädische Klinik der Medizinischen Hochschule Hannover im DIAKOVERE Annastift

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hannover Medical School
    ClinicalTrials.gov Identifier:
    NCT04297449
    Other Study ID Numbers:
    • 8198_MPG_23b_2018
    First Posted:
    Mar 5, 2020
    Last Update Posted:
    Sep 16, 2021
    Last Verified:
    Sep 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Hannover Medical School
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 16, 2021